Curis, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -11.11%142.290.0%$1319.96m
AMGNAmgen, Inc. -1.77%223.691.4%$503.68m
NVAXNovavax, Inc. -14.92%72.0278.2%$494.42m
BIIBBiogen, Inc. -0.54%219.331.8%$494.09m
GILDGilead Sciences, Inc. -0.61%68.091.0%$489.01m
BNTXBioNTech SE -3.74%141.990.0%$398.06m
REGNRegeneron Pharmaceuticals, Inc. -2.20%607.762.7%$393.89m
ILMNIllumina, Inc. -4.36%350.013.3%$362.36m
VRTXVertex Pharmaceuticals, Inc. -1.68%224.241.9%$335.21m
SNSSSunesis Pharmaceuticals, Inc. -7.93%2.440.7%$170.56m
EXASEXACT Sciences Corp. -7.20%68.7017.9%$156.51m
ARNAArena Pharmaceuticals, Inc. -0.71%89.8413.7%$130.44m
INCYIncyte Corp. -1.23%73.872.4%$128.58m
ALNYAlnylam Pharmaceuticals, Inc. -4.00%130.968.2%$120.01m
BMRNBioMarin Pharmaceutical, Inc. -2.55%82.494.2%$100.55m

Company Profile

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.